Bullpen.News From Edwin Dorsey
Get Daily Recap Feedback

Latest News

Market cap$50M–$500B
All Over $50MOver $300MOver $2BOver $10B
All Under $1BUnder $10BUnder $100BUnder $500B
SectorsAll
Filter by sector
Wednesday, October 21, 2026· 9186 stock ideas· 218 writers·
21,633 views· 10,046 clicks

Why I sold OB pick for 26 SVM

Silvercorp’s falling Ying grades, prolonged GC suspension, El Domo execution risk and Chaarat funding needs weaken its valuation despite higher silver prices.

SVM $2.1B
The Oak Bloke 7 clicks

From X

@BlueDuckCap

BDC on X

This is the fundamental reason we too like $SNAP. And the catalyst now is that a decade of Specs capital deployment with material negative ROE to date is coming to a cross roads. Either Specs shows enough promise, while fully acknowledging that the units sold this season will not be much due to price point/form factor, OR it's a pretty underwhelming event which will raise pressure to guardrail spend going forward. Wildcard would be some sort of partner announcement. We'd love that to be a minority investor in Specs such as $SPCX where we've found a lot of industrial logic. In any event, FCF per share is going up.
@KEDM_COM

KEDM.com on X

Old KEDM flag Butler National $BUKS continues to perform, and insiders are still adding shares on the open market. The last quarter (ending Jan. 2026) showed very strong, accelerating revenue growth and an EBITDA margin of>40%. As a reminder, Butler has a casino and an aerospace business (because why not). It's mainly the latter that is performing quite well. Plenty of aircraft need (military) modifications. Still 8x LTM EV/EBITDA (though EBITDA can be lumpy), strong margins, ramping cash flow, no coverage.
@kevin__mak

Kevin Mak on X

$ABVX We've been here before, about three months ago. Price is controlling the narrative again. In June people extrapolated a handful of malignancy cases into a broken thesis, the stock fell 43%, and then erased a month of losses in a single day when the next data landed. Nothing about the asset changed in either direction. I think the same thing is happening now. The price is lower, so people have decided shareholders are doomed and nobody is ever going to buy the business. The fair argument against me is that the probability of a takeout has fallen, because it hasn't happened yet. List your house, get no bids in 60 days, and that tells you something about your asking price. Silence is information. But big pharma M&A is a market with half a dozen real buyers, competing priorities, and internal politics. Deals come together in weeks or in years. The signal from "no deal yet" is extremely noisy, and people are treating it as a clean efficient market. I think the bigger problem is what shareholders were assuming in the first place. If you expected a $180-200 takeout within three months, at today's price that is a 78% return in a quarter. Call it 50/50 to be "conservative" and you are still assuming roughly 39% a quarter or 270% annualized. (Change the numbers to levels a month ago and you still get the same directional craziness) So the problem was never the price target. Targets have a defensible basis. The problem is the clock. My view: $150-200 over the next 18 months, either from a buyout or from a credible launch trajectory. From here that is 25-50% annualized, which is a number a portfolio can be built on. Roughly the same price everyone else is talking about. I just don't have the same timeline expectation. If a buyout comes sooner, that is the better outcome, not just the faster one. The asset is worth more inside a company that already has a GI salesforce than it is standalone. Disclosure: Creek Drive and its affiliated funds hold a long position in ABVX. Views expressed are current opinions for informational and educational purposes only, subject to change and are not investment advice or a recommendation to buy or sell any security. Investing involves the risk of loss and past performance is not indicative of future results. See the disclosures link in bio for more important information.

Investor Letters

All letters

Free Recaps of the best new stock ideas, delivered every morning.

Read past recaps

Carecloud News

CareCloud may attract a private-equity buyer after its Q3 call, with acquiring enough shares the main obstacle to a take-private deal.

CCLD $79M
Calvin Blissett 4 clicks

Heico Corporation

HEICO sells FAA-approved aircraft replacement parts at 30% to 50% discounts to OEMs, gaining customers as restrictive aftermarket contracts…

HEI $43B
D Invests 6 clicks
CHGG · long

Chegg Inc

Chegg is framed as a binary long with 500% upside against 20% downside.

CHGG $78M
Value Investors Club 2 clicks

Copper Fox Metals: Research Flash

Copper Fox’s C$9.1 million Schaft Creek program advances metallurgical, tailings, water and road studies toward a pre-feasibility study,…

TECK $31B
Atrium Research - Equity Research 4 clicks

AppLovin Deep Dive

AppLovin rebuilt its ad model with AXON 2.0, lifting LTM revenue to about $7 billion and margins to 77% as Unity competition threatens ad…

APP $92BU $19B
Speedwell Memos 63 clicks

LXS.DE: a 2028 sale it can force

Lanxess can force Advent to buy at least half its Envalior stake in April 2028, potentially raising about €745 million to reduce net debt.

LPTH $525M
Trade Ideas Flow 18 clicks

Build-A-Bear: A Narrower Path

Build-A-Bear's push into prestuffed toys and broader retail distribution tests brand stretchability, but recent results warrant caution.

BBW $303M
TSOH Investment Research 16 clicks

Have a source we’re missing? Send your pick

Recent recaps

Latest recap

Monday, October 19 52 stock ideas
  • 40 Stock Pitches (12th-18th October) 🖨️ Capital Employed
  • The Monday Morning Briefing: Meta, Tesla, Netflix, P&G on Deck Latticework by MOI Global
Read the recap

All recaps

Publications we follow

Every publication on this site, hand-picked.

128 publications

Newsletters 108

YouTube 4

Blogs 15

Seeking Alpha 52 of 244

Nominate a publication

X accounts we follow

Every account on this site, hand-picked.

90 accounts
Nominate an account

Investor letters we follow

189 firms

Sectors

Ordered by how often our editor reaches for them.

Anything we’re missing?

Send us a pick